Background
==========

From 1995 to 2010, the prevalence of ST-elevation myocardial infarction increased from 11.8 to 25.5% particularly in women younger than 60 years ([@B20]). As a growing number of premenopausal female patients with various cardiovascular indications, a need of anticoagulants and/or antiplatelet agents has gradually increased ([@B13]). Women taking antithrombotic therapy may experience both increased volume and duration of menstrual bleeding ([@B16]). Even though uterine structural or endocrine abnormalities are also related to AUB, the prevalence of HMB in premenopausal women under age 50 years increased from 17.8% before antithrombotic treatment to 29.5% thereafter ([@B25]). Antiplatelet therapy of aspirin and clopidogrel could also lead to AUB and HMB ([@B13]). The lacks of asking menstrual problems by the majority of cardiologist or vascular specialists in premenopausal female patients may exacerbate the risk of AUB and HMB. We report one such rare case of HMB in a 33-year-old patient after hemodialysis and antiplatelet therapy, who suffers from ACS, uremia and systemic lupus erythematosus.

Case Presentation
=================

Our patient is a 33-year-old women suffering from ACS, uremia and systemic lupus erythematosus. The patient was hospitalized on February 26th 2018 for ACS. Before the introduction of PCI, she had been treated with hemodialysis weekly at Monday, Wednesday, and Friday for years (Table [1](#T1){ref-type="table"}). At hospital admission, laboratory testing showed normal hemoglobin level of 116 g/L (Table [1](#T1){ref-type="table"}). After PCI on February 26th, 2018, the patient had received aspirin 100 mg q.d. and clopidogrel 75 mg q.d. since February 26th, 2018. On February 27th, 2018, the patient had menstrual bleeding. Due to the presence of increased volume of menstrual bleeding on the fifth day, the patient had extreme discomfort and anxiety, requiring a gynecologic consultation. The reduction of RBC count, hemoglobin and hematocrit leaded to a doubt of normocytic hypochromic anemia (Table [1](#T1){ref-type="table"}). Since March 3rd, 2018, the patient received oxytocin 20 IU q.6.h., which could reduce uterine bleeding. However, the HMB had not improved until March 5th 2018. Under the consultation of gynecologists and clinical pharmacists, we investigated whether the uterus was abnormal by using the gynecologic ultrasound, and the results suggested the presence of uterine myoma and cervical canal cyst (Figure [1](#F1){ref-type="fig"}). Testosterone propionate 25 mg q.d. and norethindrone 5 mg q.8.h. were suggested. After the administration of testosterone propionate and norethindrone, the menstrual volume of the patient was significantly reduced. This patient was discharged from hospital in March 7th, 2018. The patient medications during hospitalization were: rosuvastatin calcium tablets, mosapride citrate dispersible tablets, pantoprazole sodium enteric-coated capsules, compound glycyrrhiza oral solution, and cefdinir dispersible tablets.

###### 

Clinical information and history.

  (Normal range)                             February 26th 2018   February 28th 2018   February 28th 2018   March 2nd 2018   March 3rd 2018   March 5th 2018   March 7th 2018
  ------------------------------------------ -------------------- -------------------- -------------------- ---------------- ---------------- ---------------- ----------------
  **Hematology testing**                                                                                                                                       
  RBC (3.68--5.12 × 10^12^/L)                3.93                 \-                   \-                   \-               3.6 ↓            3.2 ↓            \-
  WBC (3.69--9.16 × 10^9^/L)                 6.50                 \-                   \-                   \-               5.72             6.57             \-
  N % (50--70 %)                             90.9 ↑               \-                   \-                   \-               72.3 ↑           88.8↑            \-
  Lymphocyte % (20--40%)                     7.4 ↓                \-                   \-                   \-               19.2 ↓           7.8↓             \-
  Monocyte % (3--10%)                        1.2 ↓                \-                   \-                   \-               7.0              2.6↓             \-
  Eosinophils % (0.5--5.0%)                  0.2 ↓                \-                   \-                   \-               1.0              0.5              \-
  Basophil % (0.0--1.0%)                     0.3                  \-                   \-                   \-               0.5              0.3              \-
  Hemoglobin (113--151 g/L)                  116                  \-                   \-                   \-               111 ↓            94 ↓             \-
  Hematocrit (0.37--0.480 L/L)               0.365 ↓              \-                   \-                   \-               0.332 ↓          0.295 ↓          \-
  MCV (82.6--99.1 fl)                        92.9                 \-                   \-                   \-               92.2             92.2             \-
  MCH (26.9--33.3 pg)                        29.5                 \-                   \-                   \-               30.8             29.4             \-
  MCHC (322--362 g/L)                        318 ↓                \-                   \-                   \-               334              319 ↓            \-
  Glucose (3.9--6.1 mmol/L)                  3.34 ↓               \-                   \-                   \-               \-               \-               \-
  HbA1c (4--6%)                              4.7                  \-                   \-                   \-               \-               \-               \-
  Triglycerides (\<1.7 mmol/L)               1.83 ↑               \-                   \-                   \-               \-               \-               \-
  Total cholesterol (\<5.72 mmol/L)          5.43                 \-                   \-                   \-               \-               \-               \-
  LDL                                        2.77                 \-                   \-                   \-               \-               \-               \-
  HDL                                        1.59                 \-                   \-                   \-               \-               \-               \-
  **Markers of kidney function**                                                                                                                               
  Creatinine (45--104 μmol/L)                1095.0 ↑             \-                   \-                   \-               \-               1081.0 ↑         \-
  Urea nitrogen (2.9--8.2 mmol/L)            28.90↑               \-                   \-                   \-               \-               25.50 ↑          \-
  **Hemodialysis**                                                                                                                                             
  Duration of hemodialysis (hours)           3                    4                    3                    4                \-               \-               4
  Ultrafiltration (mL)                       1030                 2400                 2900                 4000             \-               \-               2700
  **Markers of myocardial infarction**                                                                                                                         
  CK (30--170 U/L)                           77                   \-                   \-                   \-               \-               \-               \-
  TNI-A2 (\<0.04 ng/mL)                      6.59 ↑               \-                   \-                   \-               \-               \-               \-
  BNP (0.0--100 pg/mL)                       321.0 ↑              \-                   \-                   \-               \-               \-               \-
  PTH (12--88 pg/mL)                         1004.5 ↑             \-                   \-                   \-               \-               \-               \-
  CRP (0--3 mg/L)                            1.90                 \-                   \-                   \-               \-               \-               \-
  **Blood coagulation series detection**                                                                                                                       
  Fibrin degradation products (0--5 μg/mL)   1.2                  \-                   \-                   \-               \-               \-               \-
  Thrombin time (14--21 s)                   18.1                 \-                   \-                   \-               16.20            \-               \-
  Prothrombin time (9.4--12.5 s)             9.90                 \-                   \-                   \-               10.40            \-               \-
  Fibrinogen (2.00--4.00 g/L)                2.96                 \-                   \-                   \-               3.53             \-               \-
  Partial thromboplastin (20--40 s)          29.1                 \-                   \-                   \-               28.20            \-               \-
  Prothrombin INR (0.8--1.15)                0.85                 \-                   \-                   \-               0.91             \-               \-
  D-dimer (0--0.5 DDU μg/mL)                 0.13                 \-                   \-                   \-               \-               \-               \-
                                                                                                                                                               

RBC, red blood cell count; WBC, white blood cell; N %, neutrophil %; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin mch; MCHC, mean corpuscular hemoglobin concentration; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; HDL, high-density lipoproteins; CK, creatine kinase; TNI, troponin I; BNP, brain natriuretic peptide; PTH, parathyroid hormone; CRP, C-reactive protein. ↓, lower than normal value; ↑, higher than normal value.
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Investigations
==============

Clinical investigations were performed to assess for the causes of HMB at aspirin and clopidogrel therapeutic doses. They included *CYP2C19*, *ABCB1*, *PEAR1*, and *PON1* genotyping, and thromboelastogram.

*CYP2C19*, *ABCB1*, *PEAR1*, and *PON1* Genotyping
--------------------------------------------------

Blood samples were collected before the use of clopidogrel, which were drawn into a vacutainer tube containing 3.8% trisodium citrate. The presence of *CYP2C19^∗^2* (rs4244285), *CYP2C19^∗^3* (rs4986893) was detected via DFMH method using a commercial kit from Sino Era Genotech^[1](#fn01){ref-type="fn"}^ (Beijing, China). 200 μL of whole blood was added to 1 mL of RBC lysis buffer and incubated for 5 min at indoor temperature. Centrifuged (3,000 rpm) the mixtures for 5 min then removed the supernatant. Afterward, 50 μL of preservation solution was added to the precipitate. 1.5 μL of sample was combined with detecting reagent that includes hybridization buffer and two molecular beacon probes labeled with FAM and HEX for wild-type or mutation. TL998A real-time PCR system (Tianlong, Xi'an, China) was used to perform the analysis. The detected process began with denaturation for 5 min at 95°C followed by 55 cycles of denaturation for 30 s at 95°C and hybridization for 75 s at 62°C. Based on *CYP2C19* genotype, the patients were classified into three metabolizers, which were extensive metabolizer (EM; ^∗^1/^∗^1), intermediate metabolizer (IM; ^∗^1/^∗^2 or ^∗^1/^∗^3), or poor metabolizer (PM; ^∗^2/^∗^2, ^∗^2/^∗^3, or ^∗^3/^∗^3). *ABCB1* (rs1045642), *PEAR1* (rs12041331), and *PON1* (rs662) genotyping were also detected via DFMH method. Results indicated only a *CYP2C19^∗^2* heterozygous, lead to a classification of intermediate metabolizer in this patient (Table [2](#T2){ref-type="table"}).

###### 

The results of CYP2C19, ABCB1, PEAR1, and PON1 genotyping.

  Locus         SNP          Allele   Results
  ------------- ------------ -------- ---------
  CYP2C19^∗^2   rs4244285    G \> A   GA
  CYP2C19^∗^3   rs4986893    G \> A   GG
  ABCB1 3435    rs1045642    C \> T   CC
  PEAR1         rs12041331   G \> A   GG
  PON1 576      rs662        A \> G   AA
                                      

SNP, single nucleotide polymorphism.

Thromboelastogram
-----------------

Thromboelastograph platelet-mapping assay was used to detect platelet reactivity of aspirin and clopidogrel by using a computerized Thromboelastograph Hemostasis Analyzer system (TEG 5000; Haemoscope Corporation, Niles, IL, United States). 1 mL of whole blood was mixed with kaolin, inverted five times, and loaded in a heparinize-coated cup containing 20 μl of CaCl~2~. TEG was started to measure AA-induced (acetylsalicylic acid-induced) and ADP-induced (adenosine diphosphate-induced) platelet aggregation. Results indicated a high drug inhibition rate of platelet (Table [3](#T3){ref-type="table"}). These results lead to a higher risk of bleeding than normal.

###### 

The results of thromboelastogram.

                                                 ADP       Aspirin    Clopidogrel
  ---------------------------------------------- --------- ---------- -------------
  DIR (aspirin: 50--90%; clopidogrel: 40--90%)   N/A       100.00 ↑   93.40 ↑
  Fibrinogen level (53--72°)                     74.60 ↑   63.80      69.10
  Platelet function (50--70 mm)                  58.50     14.90 ↓    18.90 ↓
  Prediction of fibrinolysis index (0--15%)      0.00      0.00       0.00
  Fibrinolysis index (0--8%)                     0.00      0.00       0.00
  Coagulation time (min)                         22.80     8.80       7.30
  Blood clot strength (4500--11000 d/sc)         7036.90   874.80 ↓   1163.30 ↓
                                                                      

ADP, adenosine diphosphate; DIR, drug inhibition rate; ↓ lower than normal value; ↑ higher than normal value.

Discussion
==========

Female sex is an independent factor of a higher bleeding risk than male sex during cardiac interventions. After the placement of DES, DAPT including aspirin and P2Y12 receptor antagonist is commonly used for the prevention of thrombosis. Clopidogrel, as a kind of P2Y12 receptor antagonist, remains the first-line antithrombotic drug in Asian patients post DES. The presence of inappropriate dosages of antiplatelet agents and uterine fibroids could cause AUB ([@B6]). However, AUB in younger female population is often ignored or underestimated. Excessive AUB increase the risk of anemia, which could enhance ischemic heart disease. In this case, we described a 33-year-old female patient who suffered from ACS, uremia and systemic lupus erythematosus. At 6 days after PCI and DAPT with aspirin and clopidogrel, this patient complained of excessive HMB and physical discomfort for lasting 5 days. Laboratory investigations showed a reduction of RBC count, hemoglobin and hematocrit from February 26th to March 5th. A heterozygote of *CYP2C19^∗^2* lead to a intermediate metabolizer of clopidogrel. However, renal insufficiency was probably a contributing factor to an increased susceptibility to aspirin and clopidogrel. This may explain the high reactivity of aspirin and clopidogrel in TEG. Another contributing factor for excessive HMB was the use of heparin during the process of hemodialysis. This may aggravate bleeding risk in female patients when using DAPT. On the other hand, uterine myoma and cervical canal cyst may also a contributing factor for AUB.

Aspirin, in combination with clopidogrel, reduces major adverse cardiovascular events in patients with ACS managed with PCI ([@B31]). There are many genes influence clopidogrel response which lead to a need of pharmacogenomic testing to select antiplatelet therapy ([@B20]). Among those genes, *CYP2C19* genotype was well established due to the influence of clopidogrel response ([@B10]; [@B21]). The non-functional *CYP2C19^∗^2* and *^∗^3* polymorphisms impair both antiplatelet effects and bioactivation of clopidogrel ([@B2]; [@B10]). In the acute and non-acute settings, *CYP2C19* genotyping is feasible and well used in everyday clinical practice ([@B3]). Recently, beta-1,4-galactosyltransferase 2 c.909C\>T gene variant was found which might be an independent genetic predictor of clopidogrel platelet reactivity ([@B18]). There is still need a large sample GWAS of the function of beta-1,4-galactosyltransferase 2 in patient with clopidogrel. PEAR1, which triggers platelet aggregation, plays a very important role in platelet function. Genetic variants of *PEAR1* are associated with cardiovascular events in patients undergoing PCI and treated with aspirin in combination with clopidogrel ([@B17]; [@B27]; [@B30]). *PON1* gene variations may be a risk factor of bleeding after aspirin and clopidogrel therapy ([@B11]). In this case, we tested *CYP2C19*, *ABCB1*, *PEAR1*, and *PON1* gene variations which are predictors of clopidogrel platelet reactivity. A heterozygote of *CYP2C19^∗^2* lead to a intermediate metabolizer of clopidogrel, which indicated the gene variations are not responsible for the HMB in this patient.

TEG offer a method of testing the efficiency of blood coagulation in patients with higher risks of bleeding or thrombus. The relationship between gene variation and TEG are still not clear. In Chinese patients treated with clopidogrel, polymorphisms of *CYP 2C19^∗^2* play an important role in the variability of clopidogrel's curative effect and significantly affect the platelets inhibition ratio resulted from TEG ([@B28]). In addition, severely injured patients or patients with acute deep vein thrombosis are more hypercoagulable, which can explain the higher fibrinogen level of this patient ([@B26]; [@B7]). Hemodilution could also enhanced onset of coagulation ([@B22]). However, the high drug inhibition rate (DIR) of aspirin and clopidogrel may resulted by using heparin during hemodialysis ([@B19]). The high DIR of both aspirin and clopidogrel may lead to a high risk of bleeding in this patient. However, this is a patient with ACS and PCI. It is obligatory to receive aspirin and clopidogrel to avoid thrombus formation after PCI. Guideline from both Chinese experts and other countries suggested a DAPT with 100 mg aspirin q.d. po and 75 mg q.d. po clopidogrel ([@B12]; [@B29]; [@B15]).

Oxytocin is often used as a medication to facilitate childbirth. There is still lack of evidence of oxytocin being used as a hemostatic in patients with HMB. On the contrary, some evidences indicated additional of an oxytocin infusion after cesarean delivery dose not affect the overall occurrence of major obstetric hemorrhage ([@B23]). Furthermore, use of oxytocin drip during hysteroscopic endometrial resection did not significantly reduce operative blood loss ([@B24]). For the prevention of uterine bleeding after surgical evacuation of first trimester abortion, oxytocin was still not the best choice ([@B1]).

There were several data available on how to treat HMB associated with antithrombotic agents ([@B13]; [@B5]; [@B8]; [@B4]). [@B5] suggested hormonal therapy, tranexamic acid, anticoagulant management, and surgical interventions for those patients suffering from HMB. The use of oral contraceptives could significantly decreases menstrual blood loss in women with HMB ([@B5]). In addition, high-dose progestin, such as norethisterone 5 mg given three times daily, was effective in reducing menstrual blood loss in women with AUB ([@B9]). In order to reduce menstrual bleeding, oxytocin treatment was suggested by gynecologist on the fifth day of menstruation. However, 2 days of oxytocin treatment did not significantly improve HMB. Testosterone propionate and norethindrone therapy were successfully reduce HMB. Patients with AUB undergo hormone therapy have a high risk of recurrent venous thromboembolism ([@B14]). In this case, the patient undergoes three times of hemodialysis, which contained heparin in it. There is no need a further prevention of venous thromboembolism by heparin.

To the best of our knowledge, there was a rare report of HMB of women on reproduction age who were under antiplatelet therapy. Furthermore, there was no such case of whom has HMB with ACS, uremia and systemic lupus erythematosus. More clinical safety data on HMB of reproductive age women who are under antithrombotic therapy are required.

Concluding Remarks
==================

As shown in Figure [2](#F2){ref-type="fig"}, we suggest the standard evaluation process should be clearly established in such premenopausal women. In brief, information about current menstrual bleeding patterns, reproductive status, and previous history of gynecological surgery should be asked by cardiologists or clinical pharmacists before cardiac operation. Meanwhile, gynecological examination should be performed to evaluate the presence or absence of uterine diseases. Afterward, questions concerning AUB should be carried out during the initiation of antithrombotic treatment. When patients experience HMB, hormonal therapy as well as optimal antithrombotic strategy should be conducted on the basis of menstrual blood loss and corresponding hematology testing results. Collectively, intensive management should be considered in these fragile population.

![Suggested strategy for premenopausal women who suffering from ACS and/or AF. AF, atrial fibrillation; ACS, acute coronary syndromes; HMB, heavy menstrual bleeding.](fphar-09-01573-g002){#F2}
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ABCB1

:   ATP-binding cassette sub-family B member 1

ACS

:   acute coronary syndrome

AUB

:   abnormal uterine bleeding

CYP 2C19

:   cytochrome P450 2C19

DAPT

:   dual antiplatelet therapy

DES

:   drug eluting stent

DFMH

:   digital fluorescence molecular hybridization

GWAS

:   genome-wide association studies

HMB

:   heavy menstrual bleeding

PCI

:   percutaneous coronary intervention

PEAR1

:   platelet endothelial aggregation receptor 1

PON1

:   paraoxonase 1

RBC

:   red blood cell

TEG

:   thromboelastograph
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